Physician profile
Ross J Goodfellow
NPI 1992765044
$7,540.86
in general payments reported to CMS, 2019-2025
21 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $343 · 2021: $762 · 2022: $2,682 · 2023: $567 · 2024: $1,168 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434 · Travel and Lodging: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.09 |
| Travel and Lodging | $1,057.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,135.65 | 2021-2025 | Indigo System |
| Shockwave Medical, INC | $907.67 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $686.88 | 2019-2023 | Xarelto |
| Cvrx, INC. | $441.18 | 2022-2023 | Barostim Neo System |
| Medtronic, INC. | $373.86 | 2021-2025 | Hawkone, Onyx Frontier |
| Abbott Laboratories | $358.95 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Mini Trek, Aveir |
| Amgen INC. | $345.95 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $283.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $169.42 | 2019-2023 | Farxiga |
| Abiomed | $146.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.14 | 2019-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.59 | 2019-2022 | |
| Boston Scientific Corporation | $126.09 | 2020-2025 | General - Balloon Catheters |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.15 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $59.67 | 2022-2023 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.65 | 2021-2023 | |
| Impulse Dynamics (USA) INC. | $32.58 | 2022 | |
| Chiesi USA, INC. | $26.44 | 2020 | |
| Angiodynamics, INC. | $15.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.90 | 2021 | |
| Medtronic Vascular, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Goodfellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.